CERC and the EBC Club are happy to announce that the EBC main trial successfully completed recruitment this month! David Hildick-Smith, the PI, and steering committee plan to submit the 12 months primary endpoint to EuroPCR 2021 late breaking trials. Clic here to know...
CERC will be glad to meet you in England for PCR London Valves! (Link on the...
CERC was proud to participate in Africa PCR 2019...
We are proud to announce that trials managed by CERC will be presented during EuroPCR’s sessions The ARC initiative managed by CERC: the ARC HBR definitions will be presented on Wednesday, 22nd May. To know more, click...
CERC was proud to organise the third ARC HBR meeting in Washington in April 2019, this group of experts is working on the second publication on how to design and analyse trials dedicated to the high bleeding risk...
CERC has started to implement the Colibri Heart Valve CE mark trial. This balloon-expandable THV was designed with an original leaflet geometry and material enabling a reduction in the mass of cusps with the potential benefit of a larger effective orifice area even in out-of-round shapes of the frame. In combination with proprietary dry tissue preparation, this allows for a pre-mounted, pre-packaged, low profile (true 14F) delivery system. This company-sponsored trial will be conducted in ten centers in four European countries in order to enrol 60 patients with a 1-year primary endpoint and 5-year clinical and echographic follow-up. About the trial...
